BridgeMD
New treatment option for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Official title Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
ClinicalTrials.gov ID: NCT07161037
What this study is testing
What is VX-407?
VX-407 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for autosomal dominant polycystic kidney disease (adpkd).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- A pre-existing diagnosis of ADPKD as defined in the protocol
- Willing and able to comply with scheduled visits and other study procedures
- Participants with ADPKD with Mayo imaging classification (MIC) status of 1B (with htTKV ≥250 mL/m), 1C, 1D, or 1E confirmed by abdominal MRI obtained...
- Estimated glomerular filtration rate (eGFR) greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73 square meter (m\^2) Key
You likely can't join if
- History of kidney disease other than ADPKD that in the opinion of the investigator would independently impact the natural history of ADPKD
- History of solid organ or bone marrow transplantation or nephrectomy
- Ongoing renal replacement therapy or planning to start renal replacement therapy within 12 months of screening Other protocol defined...
The study team makes the final eligibility decision.
Where it's taking place
- Alabaster, Alabama, United States
- Birmingham, Alabama, United States
- Los Angeles, California, United States
- San Francisco, California, United States
- Middlebury, Connecticut, United States
- New Haven, Connecticut, United States
- Jacksonville, Florida, United States
- Atlanta, Georgia, United States
- Columbus, Georgia, United States
- Chicago, Illinois, United States
- Iowa City, Iowa, United States
- Kansas City, Kansas, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Minneapolis, Minnesota, United States
- Rochester, Minnesota, United States
- Las Vegas, Nevada, United States
- New York, New York, United States
- Cleveland, Ohio, United States
- Danville, Pennsylvania, United States
+ 19 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Alabaster, Alabama, United States; Birmingham, Alabama, United States; Los Angeles, California, United States; San Francisco, California, United States; Middlebury, Connecticut, United States; New Haven, Connecticut, United States and 33 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.